SOURCE: XenaCare Holdings, Inc.

XenaCare Holdings, Inc.

January 13, 2011 08:26 ET

XenaCare Holdings Addresses Quotation of Its Common Stock

BOCA RATON, FL--(Marketwire - January 13, 2011) - XenaCare Holdings (OTCQB: XCHO) advises shareholders that its common stock is now quoted on the OTCQB under the stock symbol: XCHO. Shareholders may receive quotations, including level 2 data and other information at:

http://www.otcmarkets.com/stock/XCHO/quote

Following the recent sale of the OTCBB, numerous issuers were no longer being quoted by the OTCBB "for failure to comply with Rule 15c-211." The Company understands that this was a technical issue between the OTCBB and market makers and does not reflect upon the securities affected, including XenaCare.

XenaCare continues to be in compliance with its SEC reporting requirements.

XenaCare is monitoring the quotation situation in order to determine whether OTCQB is a satisfactory quotation medium.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the branding, formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. XenaCare's clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.

http://www.XenaCareHoldings.com
http://www.Cobroxin.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in XenaCare's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact Information

  • Contact:
    XenaCare Holdings
    Frank Rizzo
    561-496-6676
    Email Contact